BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON, NOVARTIS, ROCHE

07-22-2021 Blog Posts

New Round of Earnings Reports Show Big Pharma Companies Riding High on Massive Profits After Three Rounds of Price Hikes During Pandemic Brand name drug makers Johnson & Johnson, Novartis, and Roche kicked off another round of earnings reports from Big Pharma for the second quarter of the year this week. All three companies bested […]

SECOND OPINION: PHARMA-BACKED REBATE RULE WOULD HIKE SENIOR PREMIUMS, BOOST DRUG COMPANY PROFITS

07-22-2021 Blog Posts

Big Pharma Wants Implementation of Misguided Policy that Does Nothing to Lower Drug Prices, Increases Manufacturer Pricing Power Big Pharma is unhappy over the prospect of lawmakers repealing the misguided Rebate Rule. “Despite railing against high drug costs on the campaign trail, lawmakers are threatening to gut a rule that would provide patients meaningful relief […]

THEY SAID IT! U.S. SENATE JUDICIARY SUBCOMMITTEE HIGHLIGHTS BIG PHARMA’S ANTI-COMPETITIVE PRACTICES

07-14-2021 Blog Posts

Lawmakers Showcase How Big Pharma’s Patent Abuse Drives Out-of-Control Prescription Drug Prices During a hearing Tuesday before the U.S. Senate Committee on the Judiciary’s Subcommittee on Competition Policy, Antitrust, and Consumer Rights, lawmakers on both sides of the aisle hammered Big Pharma for the industry’s anti-competitive and price-hiking practices. The hearing adds to the growing […]

DOSE OF REALITY: LAWMAKERS TO PROBE BIG PHARMA PATENT ABUSE AS INNOVATION EXCUSES CRUMBLE

07-13-2021 Blog Posts

U.S. Senate Judiciary Subcommittee Hearing Tuesday Will Build on Momentum for Lawmakers to Hold Big Pharma Accountable, Lower Prescription Drug Prices On Tuesday, the U.S. Senate Committee on the Judiciary’s Subcommittee on Competition Policy, Antitrust, and Consumer Rights is set to hold a hearing examining Big Pharma’s egregious anti-competitive practices that drive-up prescription drug prices. […]

BIG PHARMA WATCH: JULY PRICE HIKES CLIMB TO 52

07-7-2021 Blog Posts

Brand Name Drug Companies Stick to Business-as-Usual in Third Major Round of Pandemic Price Hikes In case you missed it, Big Pharma companies are actively engaged in price hikes on branded medications — the industry’s third major round of price increases during the pandemic. So far this month, Big Pharma has hiked prices on 52 […]

BIG PHARMA WATCH: HEADLINES SHOW BIOGEN ADHUHELM PRICING HAS REIGNITED URGENCY TO HOLD BIG PHARMA ACCOUNTABLE

06-25-2021 Blog Posts

Coverage Highlights Backlash Over Massive Price Tag for Unproven Treatment, Cost to Taxpayers and Health System Earlier this month, after the U.S. Food and Drug Administration (FDA) approved brand name drug maker Biogen’s Alzheimer’s treatment aducanumab, brand name Aduhelm, despite serious questions about the medication’s clinical benefit for patients and zero votes in favor of […]

SECOND OPINION: PFIZER’S PHONY CALL FOR LOWER DRUG COSTS

06-22-2021 Blog Posts

CEO Sidesteps Big Pharma’s Pricing Practices; Pushes Proposals That Would Boost Drug Company Profits and Incentivize Price Hikes During a recent interview on Bloomberg’s “Balance of Power,” Pfizer CEO Albert Bourla claimed the pharmaceutical industry is willing to be a helpful partner in reducing “significantly the cost of medicines.” What Bourla did not mention in […]

CSRXP: WYDEN RX PRICING PRINCIPLES ADD TO MOMENTUM IN WASHINGTON TO HOLD BIG PHARMA ACCOUNTABLE

06-22-2021 Blog Posts

Lawmakers Must Advance Solutions to Lower Drug Prices  For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Tuesday on the release of drug pricing principles from U.S. Senate Committee on Finance Chairman Ron Wyden (D-OR). “CSRxP commends Chairman Wyden for his leadership and dedication to […]

WHAT THEY ARE SAYING: BIOGEN’S “SIMPLY UNACCEPTABLE” ADUCANUMAB PRICING HIGHLIGHTS URGENCY FOR RX SOLUTIONS

06-14-2021 Blog Posts

Broad-based Opposition to Egregious Launch Price on Drug With Unproven Clinical Benefit Adds to Momentum to Hold Big Pharma Accountable Last week, the U.S. Food and Drug Administration (FDA) approved Alzheimer’s treatment aducanumab, brand name Aduhelm, despite serious questions about the medication’s clinical benefit for patients and a unanimous vote against moving forward from the […]

ICYMI: BIG PHARMA’S FASTER-THAN-INFLATION PRICE HIKES COSTING MEDICARE BILLIONS OF DOLLARS

06-7-2021 Blog Posts

AARP Study Finds Brand Name Drug Companies Increased Prices Above Rate of Inflation on 90 Percent of Best-Selling Part D Medications In case you missed it, AARP released a new report Monday detailing how drug price increases that exceed the rate of inflation are costing the Medicare Part D program billions of dollars in additional […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.